Literature DB >> 23562482

Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread.

Marcy Auerbach1, Donghong Yan, Ashley Fouts, Min Xu, Alberto Estevez, Cary D Austin, Fernando Bazan, Becket Feierbach.   

Abstract

In human cytomegalovirus (HCMV), the UL128-131A locus plays an essential role in cellular tropism and spread. Here, we report the complete annotation of the GP129-133 locus from guinea pig cytomegalovirus (GPCMV) and the discovery of the UL131A homolog, named GP133. We have found that similar to HCMV the GP129-133 proteins form a pentamer complex with the GPCMV glycoproteins gH and gL. In addition, we find that the GP129-133 proteins play a critical role in entry as the GP129-133 deletion mutant shows a defect in both endothelial and fibroblast cell entry. Although the GP129-133 deletion strain can propagate in vitro, we find that the deletion fails to spread in vivo. Interestingly, the wildtype strain can spontaneously give rise to the GP129-133 deletion strain during in vivo spread, suggesting genetic instability at this locus.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562482     DOI: 10.1016/j.virol.2013.03.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Specialization for Cell-Free or Cell-to-Cell Spread of BAC-Cloned Human Cytomegalovirus Strains Is Determined by Factors beyond the UL128-131 and RL13 Loci.

Authors:  Eric P Schultz; Jean-Marc Lanchy; Le Zhang Day; Qin Yu; Christopher Peterson; Jessica Preece; Brent J Ryckman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Authors:  Mark R Schleiss; Craig J Bierle; Elizabeth C Swanson; Michael A McVoy; Jian Ben Wang; Zainab Al-Mahdi; Adam P Geballe
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

4.  Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  Vaccine       Date:  2020-01-31       Impact factor: 3.641

Review 5.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

Review 6.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

7.  Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.

Authors:  Michael A McVoy; Jian Ben Wang; Dirk P Dittmer; Craig J Bierle; Elizabeth C Swanson; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jason C Zabeli; Mark R Schleiss
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

8.  Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors:  Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2015-06-13       Impact factor: 3.641

9.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

10.  An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Authors:  Mark R Schleiss; Ryan Buus; K Yeon Choi; Alistair McGregor
Journal:  Future Virol       Date:  2013-12-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.